DUBLIN–(BUSINESS WIRE)–The “North America Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Country: Trend Forecast and Growth Opportunity” report has been added to ResearchAndMarkets.com’s offering.
North America influenza treatment market is expected to grow by 2.3% annually in the forecast period and reach $569.8 million by 2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment in the region.
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Country.
Highlighted with 23 tables and 40 figures, this report is based on a comprehensive research of the entire North America influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
Scope of the Report
Based on Product Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oseltamivir Phosphate
- Baloxavir Marboxil
- Peramivir
- Zanamivir
- Other Drugs
Based on Influenza Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Influenza A
- Influenza B
- Influenza C
Based on Administration Route, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Oral Administration
- Other Administration Routes
Based on Distribution Channel, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Retail Pharmacy
- Hospital Pharmacy
- Clinics
- Online Stores
Geographically, the following national/local markets are fully investigated:
- U.S.
- Canada
- Mexico
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in North America influenza treatment market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players
- AstraZeneca Plc
- BioCryst Pharmaceuticals Inc.
- Biondvax
- Daiichi Sankyo Company
- F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.)
- GlaxoSmithKline Plc
- Mylan N.V
- Natco Pharma Limited
- Novartis AG
- Sanofi
- Seqirus
- Teva Pharmaceutical Industries Limited
For more information about this report visit https://www.researchandmarkets.com/r/he78ai
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900